bioRxiv · 10.1101/2025.10.15.682549
Durability of DNA-LNP and mRNA-LNP Vaccine-Induced Immunity Against SARS-CoV-2 XBB.1.5
Abstract
mRNA-lipid nanoparticle (LNP) vaccines induce robust adaptive immune responses and have proven highly effective against SARS-CoV-2. However, their long-term effectiveness is limited by waning humoral responses, which decline substantially within the first six months post-boost vaccination. DNA-LNPs are being investigated as an alternative vaccine platform, offering prolonged antigen expression and robust immunity. Here, we present the first comparison of SARS-CoV-2 DNA- and mRNA-LNP vaccines in a long-term in vivo challenge model. Both nucleic acid platforms induced strong neutralizing antibody responses and conferred equivalent protection in Syrian hamsters challenged three weeks post-boost. Notably, DNA-LNP vaccination maintained high binding and neutralizing antibody titers six months post-boost, whereas mRNA-LNPs exhibited a marked decline. Correspondingly, while DNA-LNPs completely protected from weight loss, viral replication, and lung pathology at this late timepoint, mRNA-LNP vaccination conferred minimal protection. These findings demonstrate that DNA-LNPs can sustain durable immunity, highlighting their potential as a next-generation vaccine platform that could reduce the need for frequent boosters.
Source connections
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Tamming, L., Lansdell, C., Zhang, W., Duque, D., Bavananthasivam, J., Frahm, G., Pfeifle, A., Thulasi Raman, S. N., Wu, J., Gravel, C., Stalker, A., Stuible, M., Durocher, Y., Chen, W., Wang, L., Sauve, S., Tran, A., Johnston, M. J. W., Li, X.. 2025-10-15. Durability of DNA-LNP and mRNA-LNP Vaccine-Induced Immunity Against SARS-CoV-2 XBB.1.5. https://doi.org/10.1101/2025.10.15.682549
Cite the original work for its findings. Save a collection to share your selection of sources.